Close Menu

NEW YORK (GenomeWeb) – The US Food and Drug Administration has accepted Myriad Genetics' supplementary premarket approval application for BRACAnalysis CDx as a test that may be used to identify metastatic breast cancer patients who are most likely to respond to AstraZeneca's Lynparza (olaparib).

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The New York Times reports on an effort to address in high school biology classes misconceptions regarding race and genetics.

60 Minutes speaks with Harvard's George Church about tackling the effects of aging and more.

In PLOS this week: rare alterations in Timothy syndrome, analysis of twins' gut microbiomes, and more.

GenomeWeb reports that Veritas Genetics is suspending its US operations.